The evolution of beta-agonists.
Publication/Presentation Date
12-1-1999
Abstract
Inhaled beta-agonists have become the mainstay of bronchodilator therapy for reactive airway diseases, either alone or in conjunction with other medications. The history of the development of beta-agonists is a fascinating one that spans more than 5000 years. Scientific investigation for the past several hundred years has elucidated the physiology of bronchoconstriction and bronchodilation. In the past decade, a wealth of knowledge has come forth since the discovery of the beta-adrenoceptor which, along with advances in pharmacology, have helped answer the questions of how beta-agonists work. From these advancements, three classes of beta-agonists have been developed: catecholamines, resorcinols, and saligenins. The chemical structures of the more commonly used agents in each class, their interaction with the beta-adrenoceptor, and their beneficial and adverse effects are discussed. Review of the duration of action of these agents may suggest a new way of classifying them into ultrashort-acting, short-acting, intermediate-acting, and long-acting.
Volume
5
Issue
4
First Page
479
Last Page
519
ISSN
1078-5337
Published In/Presented At
Aranson, R., & Rau, J. L., Jr (1999). The evolution of beta-agonists. Respiratory care clinics of North America, 5(4), 479–519.
Disciplines
Medicine and Health Sciences
PubMedID
10565878
Department(s)
Department of Medicine
Document Type
Article